Transcript Highlights:

• Any advertising for compounded drugs must be truthful and clearly state that these products are compounded
• Well, with the compounding pharmacies, you can have it compound into your needs specifically.
• I do have to know, is it possible for a compounder, a compounding pharmacy, under the provisions of this
• ... ...compounders.
• think compounders should have to tell that.

Summary: The committee heard several bills focused on privacy, accessibility, labor, and public safety. AB 1798 by Assemblymember Wilson would bar life and disability insurers from using non-diagnostic genetic information, including direct-to-consumer test results, in underwriting. Supporters argued the bill would protect privacy and encourage genetic testing, while insurers opposed it as unnecessary and said genetic data should be treated like other predictive health information. The bill passed the committee on a 7-0 vote and was held open for absent members. AB 2190 by Assemblymember Wallace would create website accessibility standards based on WCAG guidelines and add affirmative defenses intended to reduce serial litigation while improving access for people with disabilities. Disability advocates supported the measure as a needed civil-rights update, while business groups warned it could increase liability and create unclear compliance obligations. The bill passed 9-0 and was sent to Appropriations. AB 2721 by Assemblymember Carrillo would require hotels to post notice when they know or should know that U.S. Customs and Border Protection or ICE are using the premises, with supporters saying workers and guests deserve transparency and safety. Hotel and business groups opposed it, citing privacy, liability, and concerns about interfering with federal operations. The committee voted 6-2 to pass the bill to Appropriations, with the roll left open. AB 2027 by Assemblymember Ward would restrict employers from using worker data to train AI systems that replace workers and limit sharing of worker data for automation; labor groups supported it and business and public-sector groups opposed it as too broad. The bill passed 7-2 to Appropriations, with the roll left open. The committee also heard AB 1837 by Assemblymember Mark Gonzalez, which would extend and tighten privacy rules for transit agencies’ use of forward-facing cameras to enforce bus-lane violations; supporters said the cameras improve transit flow and safety, and the bill was presented with amendments, though no final vote is reflected in the transcript excerpt.

Transcript Highlights:

• compounding.
• at Drake University. pharmaceutical industry is profound and pharmaceutical industry is profound and
• </c> excellence in pharmaceutical excellence in pharmaceutical compounding.<00:14:53.279><c> Prior</c
• </c> compounding. Prior to his tenure, Mr. compounding. Prior to his tenure, Mr.
• </c> Compounding Expert Committee. Mr. Compounding Expert Committee. Mr.

Keywords: U.S. House of Representatives Floor Proceedings on Tuesday, April 29, 2025, 1012, house, all

Transcript Highlights:

• I agree that it's very clear that we need to focus on pharmaceutical manufacturers, pharmaceutical benefit
• That's far in excess of any pharmaceutical company, quite honestly.
• A new Office of Pharmaceutical Policy and Analysis was created within HPC.
• A new Office of Pharmaceutical Policy and Analysis was created within HPC.
• So basically the pharmaceutical companies don't have leverage against the PBMs? Yeah.

Keywords: 995, all

Summary: The Joint Committee on Health Care Financing held a public hearing on a broad set of health care bills focused on cost, market oversight, pharmaceutical access, transparency, hospital closures, and pharmacy access. Chairs John Lawn and Cindy Friedman opened by emphasizing recent health care reforms and the need for further action on the drug supply chain, PBMs, private equity, and affordability. The committee heard testimony on several measures, including a Betsy Lehman Center bill to make technical changes and create a permanent trust account for federal and private funding, and bills on hospital profits and fairness, hospital closures and health planning, pharmacy deserts, and health care market oversight and pharmaceutical access. No votes were taken during the hearing. On the hospital profits bill, physicians and labor advocates strongly supported capping hospital CEO compensation at 50 times the lowest-paid worker, requiring greater financial transparency, and directing penalties from high-margin public hospitals into a Medicaid reimbursement fund. Testifiers argued that executive pay is excessive while frontline staff and safety-net services are under strain. Committee members raised concerns about unintended consequences, including whether hospitals might shift workers to contract status or lose executive talent, and whether the bill would actually direct money to the safety net. Supporters responded that the measure is one piece of a larger effort and that the bill’s Medicaid reimbursement provisions would help underserved hospitals. Testimony on market oversight and pharmaceutical access centered on rising health care and drug costs, PBM practices, and the proposal to give the Health Policy Commission authority to set upper payment limits for certain drugs. Consumer advocates, disability advocates, an independent pharmacist, the Attorney General’s office, and others supported stronger oversight, citing premium increases, affordability problems, and the impact of high drug prices on patients and community pharmacies. Pharma and some industry witnesses opposed parts of the bill, warning that upper payment limits could disrupt access, create legal issues, and fail to address the broader supply chain. The committee also heard support for stronger hospital closure notice and public hearing requirements, and for a pharmacy deserts bill aimed at identifying and addressing closures like the one in Roxbury that affected thousands of patients.

Transcript Highlights:

• And it's important that regulation should be free from the influence of the cannabis and pharmaceutical
• It was passed in 2016, and it requires any pharmaceutical product manufacturer selling or distributing
• And when you looked behind the veil of My Old Meds, it was the pharmaceutical industry.
• As with any promising compound, we need controlled, well-designed clinical trials to fully understand
• And the amazing research of Massachusetts, the chance to explore this compound scientifically, safely

Keywords: 995, all

Summary: The hearing opened with remarks from House Chair Mindy Domb and Senate Vice Chair Robyn Kennedy, who outlined procedures for the hybrid public hearing, noted the committee would hear testimony on 15 bills related to treatment settings, and recognized members present. The first major bill discussed was H. 4200, authorizing a pilot program for psychedelic-assisted treatment in licensed facilities. Representative Jim O’Day and witnesses from Control Z supported the bill, describing it as a tightly controlled, medically supervised pilot with DPH oversight, limited sites, and screening requirements. Committee members asked about the number of sites and whether Column Health still existed; witnesses said the bill contemplated three separate pilot programs and that Column Health no longer existed after being purchased by another company. The committee also heard testimony on S. 1405 to make the drug stewardship program permanent by removing its 2026 sunset date. Senator John Keenan and others said the program helps collect and safely dispose of unused medications, reduces diversion, and should remain in place because manufacturers should bear disposal costs. A member from Boston added support based on local concerns about people searching through bags for drugs, and Keenan explained the original sunset reflected pilot status and industry pushback. A large portion of the hearing focused on S. 1394 and H. 2193, which would strengthen implementation of the 2023 Roadmap for Behavioral Health Reform. The Children’s Mental Health Campaign, Parent/Professional Advocacy League, Massachusetts Association for Mental Health, and Elliott Community Human Services testified that the roadmap’s helpline, community behavioral health centers, and crisis services are important but unevenly implemented. They urged a single point of accountability within EOHHS, regular strategic planning, a public data dashboard, and financial analysis of the behavioral health system and the access and crisis intervention trust fund. Witnesses said commercial insurance often does not fully reimburse community behavioral health center services, making sustainability difficult, and asked for better coordination across agencies and crisis response systems. Committee members asked whether the roadmap includes substance use disorder; witnesses said it is intended to cover behavioral health broadly, including mental health and substance use. The committee also heard testimony on bills to ban aversives and on suicide prevention signage. Lisa Jean Graff testified in support of S. 1394 by urging a statewide ban on aversive practices, including electric shock, withholding food or bathroom access, and other painful interventions, arguing disabled people deserve the same protections from harm as others. Fonda Bryant and Carol McLean supported a bill requiring suicide prevention signs on tall parking garages, describing personal experiences and saying the signs could create a brief pause and connect people to 988 or other help. McLean said her son died by suicide from a parking garage and that signage might have made a difference. The committee also heard strong testimony in support of creating intensive stabilization and treatment units within DMH facilities (S. 1398/H. 2204), with the Massachusetts Nurses Association and a DMH nurse arguing that highly assaultive patients need specialized, more secure units to protect staff and other patients and to improve care. Additional testimony supported creating a dedicated board for licensed mental health counselors (H. 4696/S. 1382), with Rep. John Badger, the Mass Mental Health Counselors Association, and others saying LMHCs are a large and growing workforce that needs its own licensing board, clearer standards, and faster implementation of existing licensure reforms. The committee also heard extensive testimony on H. 2223 regarding benzodiazepines and non-benzodiazepine hypnotics. Survivors and advocates described severe withdrawal, lack of informed consent, cognitive harms, and long-term disability, while a physician supported the bill as a way to improve disclosure of risks. Finally, the committee heard multiple witnesses in favor of H. 2231/S. 1383 to establish peer-run respite centers statewide. Advocates and people with lived experience said peer respites provide non-coercive, home-like alternatives to hospitalization, can reduce trauma and repeated admissions, and may be especially important for marginalized communities; they also cited cost savings and existing positive outcomes from current respite programs. No votes or final committee actions were taken during the hearing portion reflected in the transcript.

Transcript Highlights:

• other regions lead, namely Oregon, they've already treated thousands of people with this particular compound
• Colorado just began. ...of people with this particular compound.
• Even as big corporate farmers line up to commercialize these compounds.
• Even the mass public health alliance that testified prior is really a lobbying group for the pharmaceutical
• These people are not some lobbying group for the pharmaceutical industry.

Keywords: 995, all

Summary: The committee heard testimony on a wide range of public health and emergency services bills, with many speakers focusing on EMS system failures, hospital service closures, trauma preparedness, epilepsy awareness, drink-spiking response, sudden cardiac arrest, and survivor financial assistance. Several legislators and advocates described the EMS system as underfunded and overstretched, citing long ambulance waits, staffing shortages, and the need for statewide oversight, a special commission, and clearer recognition of EMS as an essential service. A number of speakers also supported bills to preserve essential hospital services after closures such as Nashoba Valley Medical Center and birthing services in Leominster, arguing that current closure rules lack enforcement and leave communities without critical care. Multiple panels testified in support of bills requiring trauma kits in public buildings, public education on SUDEP and epilepsy mortality, and improved cardiac arrest response. Supporters of the trauma-kit bill said public buildings should have bleeding-control kits and trained staff, comparing them to AEDs and first aid supplies. Epilepsy advocates, clinicians, and grieving parents urged a public health campaign on SUDEP, saying families are often not warned about the risk and that awareness could improve medication adherence, reduce guilt, and save lives. On cardiac arrest, EMS professionals and the American Heart Association backed measures to improve telecommunicator CPR, create an AED registry, and strengthen dispatch and training standards. The committee also heard extensive testimony on a bill addressing illicit drink spiking. Senators, city officials, victims, physicians, and an international anti-spiking advocate described cases in which hospitals refused toxicology testing unless a sexual assault was reported, and argued for standardized testing protocols, better data collection, and coordination with law enforcement and licensed venues. Another bill drew a sharp exchange over local public health control and the SAFE 2.0 law, with one senator arguing for more local approval and voluntary participation, while committee members defended the earlier law as a response to inequities in local public health capacity. Finally, advocates from Jane Doe, Inc. supported legislation to provide flexible financial assistance to survivors of domestic and sexual violence, saying unrestricted cash helps survivors meet basic needs, escape abuse, and rebuild stability.

Transcript Highlights:

• By way of background, psilocybin is a naturally occurring psychoactive chemical compound produced in
• Psilocybin is a naturally occurring psychoactive chemical compound produced in some species of mushrooms
• of my professional work involves setting up manufacturing facilities and testing programs for pharmaceutical-grade
• Senate Bill 5921 applies pharmaceutical manufacturing and testing standards to naturally derived psilocybin
• across the spectrum of the 340B program, both on the clinics and hospitals, as well as pharma, the pharmaceutical

Bills: SB5921, SB5185, SB6182, SB6115, SB6258, SB5916, SB5981, SB5985, SB6019, SB6161, SB6183

Keywords: psilocybin, mental health, therapy, decriminalization, legalization, international medical graduates, preceptorship, hardship pathways, medical practice, licensure, abortion, reproductive health, pregnancy termination, clinic access, abortion access fund, abortion savings account, health carrier assessment, insurance assessment, health insurer tax, Department of Health

Transcript Highlights:

• realize the dire situation in the state of Missouri as far as our budget and what will be even compounded
• And like I said, I have lived. ...compounded in March next year. So we will be looking at that.
• are going to not see any increased fees, which we continue to see year after year just due to pharmaceutical
• Everything goes up, and I... ...pharmaceutical manufacturer costs. Everything goes up.
• plan sponsor, which in turn means that we have to spend more on internal staff, actuaries, and pharmaceutical

Keywords: 959, house, all

Transcript Highlights:

• They were overloaded with requests for different PAST compounds because there are hundreds of them, as
• um they were overloaded with compounds um they were overloaded with requests<00:42:28.160><c> for</c
• ><00:42:28.400><c> different</c><00:42:28.680><c> Pas</c><00:42:29.200><c> compounds</c> requests for
• different Pas compounds requests for different Pas compounds because<00:42:29.960><c> there</c><00:42
• The PCA often, with things like pharmaceuticals, has looked at toxicity to fish on some of those things

Keywords: 1183, house

Transcript Highlights:

• point to make that there's a highly regulated industry, everybody, be it doctors, hospitals, pharmaceutical
• That complexity is compounded by union plans, association plans, and different ways of buying direct
• Like they negotiate down your pharmaceutical prices, they negotiate down the hospitals.
• And then is it compounded or not? Is there any difference in what a person is paying?
• We don't cover compounding. We just cover, you know, through our standard pharmacy benefit.

Keywords: 1184, house, all

Transcript Highlights:

• We cannot wait for an FDA-approved pharmaceutical version of a treatment that readily exists in nature
• We cannot wait for an FDA approved pharmaceutical version of a treatment that readily exists in nature
• that language was included to derive the psilocybin from actual mushrooms rather than synthesized compounds
• language was included to derive the psilocybin from actual much mushrooms rather than synthesized compounds

Keywords: 1183, house

Transcript Highlights:

• Three years is better than five years because we are compounding a problem in rural Oklahoma.
• We know these fluorocarbons and we know this material when you flush pharmaceuticals down the toilet
• Are you testing for these things, especially I'm interested in the PFOS and the pharmaceuticals?
• And also for pharmaceuticals and byproducts, or is that not currently being done? No, ma'am.
• Second of all, I think the Standards are weak from EPA on all the metals in the pharmaceuticals.

Bills: HB3005, HB3007, HB3403, HB1907, HB3175, HB3986, HB3466, HB3411, HB4246

Keywords: climatology, emergency declaration, Oklahoma Climatological Survey, environment, weather data, public policy, state governance, natural resources, advisory councils, sunset law, water quality, hazardous waste, solid waste, radiation management, public health, biosolids, land application, environmental quality, agriculture, wastewater treatment

Bills: SB8, SB4, SB43, SB1, SB2, SB13, SB6, SB10, SB16, SB14, SB3, SB8, SB4, SB43, SB1, SB2, SB13, SB6, SB10, SB16, SB14, SB3

Keywords: education, accountability, public school assessment, state law, transparency, intervention, performance ratings, Texas congressional redistricting, U.S. House districts, congressional map, redistricting, gerrymandering, 2020 Census, census tracts, block groups, voting districts, election law, Texas House of Representatives districts, federal congressional districts, 2026 elections

Transcript Highlights:

• My body is pharmaceutical resistant.
• My body is pharmaceuticals did for me. My body is pharmaceutical<02:49:54.479><c> resistant.
• If I don't pharmaceutical resistant.
• They are studying it right now to turn it into a pharmaceutical.
• </c><02:54:22.160><c> and</c> later I refused all pharmaceuticals and later I refused all pharmaceuticals

Keywords: 1191, senate, all

Transcript Highlights:

• manufactures a kratum product with synthetic mitragynine, synthetic 7-OH, or other synthetically derived compound
• We believe in bans on synthetic compounds, and we believe in comprehensive labeling requirements, as
• I think this issue is stemming from this distinction between synthetic compounds that are masquerading
• I don't believe in taking pharmaceuticals to mask anything because I just don't believe in any kind of
• I don't believe in taking pharmaceuticals to mask anything because it's, I just don't believe in, you

Bills: HB2291, HB2629, HB2439, HB1078, HB1701, HB2207, HB2501, HB2361, HB1932

Keywords: kratom, consumer protection, regulation, health safety, substance control, infrastructure, protection, safety, security, state regulations, public health, tobacco regulation, smoking cessation, vapor products, health policy, youth prevention, pet insurance, insurance regulation, animal welfare, claims processes

Transcript Highlights:

• It is a choice that is. been compounded by bad habits over time.
• Giving some more specifics in terms of types of exercise, also compound lifts.
• medical education. our medical establishment, they call it Rockefeller Medicine, all based on pharmaceuticals
• There's no pill, no pharmaceutical in the world that'll raise life expectancy by three years.

Keywords: health policy, lifespan, quality of life, community health, public testimony

Summary: The committee meeting was marked by discussions surrounding health policies aimed at enhancing the lifespan and quality of life for the community members. The chairperson initiated the session with personal reflections on the importance of extending not just the years of life but also the quality of those years, especially from the perspective of parents and grandparents. Members engaged in thoughtful dialogue regarding potential legislative measures that could address public health in a more holistic manner, emphasizing the need for community outreach and effective health education programs.

Transcript Highlights:

• But you need your pharmaceutical partner to actually want to provide a rebate.
• When I met the advocates, the pharmaceutical folks.
• Browning, so you represent Otsuka, American Pharmaceutical.
• This is not some chemical compound.
• This is not some chemical compound.

Summary: The committee heard several bills related to radiation protection in cardiac catheterization labs and later a stem cell/regenerative therapy bill. On SB 1121, which would allow hospitals with radiation protection systems to let clinicians forgo lead aprons if they work in the designated safety area and use real-time dosimetry, testimony was largely supportive or neutral after a late amendment gave radiation safety officers discretion to require protective gear if exposures approach thresholds. The committee adopted the amendment and passed SB 1121 on a 9-1 vote. SB 1120, a more prescriptive bill requiring at least 50% of cath lab rooms in hospitals to be equipped with the radiation protection system, drew divided testimony: sponsors and several physicians argued it would reduce orthopedic injury and radiation exposure and improve recruitment and retention, while hospital and radiology groups objected to the mandate, cost, limited vendor pool, and lack of clarity in the bill’s definitions. After adopting an amendment excluding children’s hospitals, the committee deadlocked 6-6 and SB 1120 failed to pass. The committee then considered SB 1118, which would appropriate $3 million to help rural hospitals install radiation protection systems in cath lab rooms. The sponsor said the funding would help rural facilities meet the same safety goals, and the committee passed the bill 6-5. The committee also heard SB 1214, a “guardrails” bill regulating non-FDA-approved stem cell and regenerative therapies, requiring informed consent, sourcing and reporting standards, advertising limits, and civil penalties for violations. Supporters said it would protect patients while allowing access to promising therapies; some members raised concerns about evidence and commercialization, but after adopting a technical amendment, the bill passed 9-3. The transcript ended as the committee moved on to SB 1630, which would seek federal approval for a home- and community-based service benefit for adults with serious mental illness; the sponsor described it as a capped, Medicaid-based community care option, and Access testified neutral while estimating a fiscal impact, but no final action on SB 1630 appears in the excerpt.

Transcript Highlights:

• Kennedy:** Senator, you're asking me not to sue pharmaceutical companies.
• Half the pharmaceutical drugs on earth are now...
• Now sold here, seventy percent of the profits from pharmaceutical companies are from the United States
• Not only that, but a recent study by a Cochrane Collaboration founder, Peter Ghosh, found that pharmaceutical
• question of whether the stability is there to be in charge of this major organization, and that's compounded

Transcript Highlights:

• But a couple years ago, the FDA approved the first pharmaceuticals, monoclonal antibiotics. antibodies
• And some of those drugs are not actually pharmaceuticals.
• And we also hear about the pro-inflammatory compounds that are part of the diet.
• Representative Frank, what you brought up about pharmaceutical companies.
• Anyway, we would submit that the development of pharmaceuticals is best left with pharmaceuticals.

Bills: HB5, HJR3, HB155, HB513, HB5, HB155

Keywords: dementia, research, health care, Texas Institute, grants, medical breakthroughs, oversight, prevention, funding, healthcare, Texas, autopsy, confidentiality, public records, medical examiner, law enforcement, HB 513, surgical smoke, surgical plume, smoke evacuation

Transcript Highlights:

• the trauma was not just from the moments where I was in a facility; the trauma was consistently compounded
• and The moments where I was in a facility, the trauma was consistently compounded and relived every
• It is the state acknowledging that kratom's compounds are dangerous enough for Class A control.
• It is the state acknowledging that Kratum's compounds are dangerous enough for Class A control.
• After exhausting all pharmaceutical options and experiencing serious adverse events, I found kratom to

Keywords: 995, all

Summary: The Joint Committee on the Judiciary held a lengthy hearing on several juvenile justice and parole-related bills, with much of the testimony focused on H. 2051/S. 1087 to end lifetime parole for juveniles and emerging adults, and H. 1923 to raise the age of juvenile court jurisdiction to include 18-, 19-, and 20-year-olds. Chairs Brandy Fluker-Reid and Lydia Edwards opened the hearing by noting the large number of bills and witnesses, the need to keep testimony moving, and special procedures for incarcerated witnesses and sensitive testimony. They also acknowledged the historic nature of the hearing being chaired by two Black women attorneys. No votes were taken during the hearing itself. Many incarcerated speakers and advocates supported ending lifetime parole, arguing that young people can change, that lifetime supervision creates constant fear of technical violations, and that it undermines rehabilitation, family stability, employment, and reintegration. Several testified about their own trauma, youth, and growth in prison programs, while others emphasized the costs of decades of supervision and the racial disparities in the system. Support also came from elected officials, UTEC, the Transformational Prison Project, United Way, CPCS’s Youth Advocacy Division, the Massachusetts Coalition to Prevent Gun Violence, and others, who said juvenile systems are better suited to developmentally appropriate treatment and that the bills would improve public safety and reduce recidivism. There was also opposition, including testimony from family members of a murder victim who argued that lifetime parole should remain for serious violent crimes and that some offenders are not sufficiently rehabilitated. One virtual witness described a family tragedy involving the kidnapping and murder of her infant nephew and warned that ending lifetime parole could remove needed long-term supervision for dangerous offenders. In addition to the juvenile justice bills, the committee heard testimony on H. 1867, a bill related to continuing care for severe mental illness, and H. 2063, which would increase penalties for assaults on correction officers and other prison staff; the correction officers’ union supported H. 2063 and related safety bills. The hearing continued with many more witnesses and bill topics, but no final committee action was announced in the portion provided.

Transcript Highlights:

• that the xylazine that is found in the Commonwealth's illicit drug supply is most often a non-pharmaceutical-grade
• compound that is not regulated by the FDA.
• Grade compound that is not regulated by the FDA.
• And I certainly think that pharmaceutical providers might fall in that category of an audience that the
• To Commissioner Gates' point, this may be something that also extends to pharmaceutical providers and

Summary: The Special Commission on xylazine convened a public meeting to review and discuss the first draft of its final report, approve prior minutes, and gather feedback for revisions. The commission first approved the December 11 minutes by roll call vote, then reviewed the report structure, which will include a commission overview, working group findings and recommendations, and appendices with public meeting materials and public resources. Staff explained the report’s framing of xylazine as both a licensed veterinary drug and an illicit drug supply contaminant, and members discussed the distinction between legal animal use and illicit importation/adulteration, with several commissioners emphasizing that people who use drugs do not intentionally seek xylazine. The commission then walked through draft findings and recommendations for best practices in oversight and enforcement, outreach and treatment, and education and training. Members discussed whether xylazine should be further scheduled or instead addressed through other public health and enforcement measures, with the draft leaning toward maintaining the current Schedule 6 status while strengthening public health responses, surveillance, drug checking, and targeted enforcement against illicit production and distribution. Commissioners also proposed stronger coordination among public safety, law enforcement, and public health, including real-time alerts, centralized data sharing, and possibly a DPH task force on emerging drug supply threats. The outreach and treatment section focused on existing harm reduction, wound care, naloxone, and mobile/low-threshold services, while noting gaps such as lack of an FDA-approved human reversal agent, geographic access barriers, insurance issues, and limited provider familiarity. A substantial portion of the meeting focused on education and training for first responders, clinicians, non-clinicians, and people who use drugs and their families. Commissioners supported tailored, stigma-free materials that cover xylazine basics, signs and symptoms, wound care, withdrawal, harm reduction, and when to seek medical care, with repeated emphasis on including firefighters, EMS, law enforcement, and other first responders in definitions and training. Members also stressed the need for consistent, centralized, and up-to-date public health data, better communication of emerging contaminants beyond xylazine, and practical guidance to prevent people with xylazine-related wounds from being turned away from care or recovery settings. The meeting ended with agreement to incorporate the feedback into a revised draft to be circulated by March 2, with another meeting scheduled for March 9 and a backup meeting later in March if needed; the commission then adjourned by unanimous motion.